Activation of estrogen receptor-β by a special extract of Rheum rhaponticum (ERr 731®), its aglycones and structurally related compounds

Journal of Steroid Biochemistry and Molecular Biology

Volumn 107, Issue 3-5, 2007, Pages 191-201

  Wober, Jannette ^a   Möller, Frank ^a   Richter, Tobias ^a   Unger, Catharina ^a   Weigt, Carmen ^a   Jandausch, Anett ^a   Zierau, Oliver ^a   Rettenberger, Reinhard ^b   Kaszkin Bettag, Marietta ^c   Vollmer, Günter ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Carl Mueller Apotheker GmbH U Co KG   (Germany)

^c Health Research Services Ltd   (Germany)

Author keywords

Climacteric; Desoxyrhapontigenin; Endometrial cells; ERE; Estrogen receptor; Hydroxystilbenes; Menopause; Phytoestrol N; Piceatannol; Resveratrol; Rhapontigenin

Indexed keywords

AGLYCONE; ANTIESTROGEN; DESOXYRHAPONTIGENIN; ERR 731; ESTROGEN RECEPTOR BETA; FULVESTRANT; LUCIFERASE; PHYTOESTROL; PICEATANNOL; PLANT EXTRACT; RESVERATROL; RHEUM RHAPONTICUM EXTRACT; TRANS RHAPONTIGENIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; YEAST CELL;

CELL LINE, TUMOR; ESTROGEN RECEPTOR BETA; HUMANS; MOLECULAR STRUCTURE; PLANT EXTRACTS; RHEUM;

RHEUM RHAPONTICUM;

EID: 34548569266     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.04.002     Document Type: Article

References (54)

1. Lindsay R., and Tohme J.F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynecol. 76 2 (1990) 290-295
2. Skafar D.F., Xu R., Morales J., Ram J., and Sowers J.R. Clinical review 91: female sex hormones and cardiovascular disease in women. J. Clin. Endocrinol. Metab. 82 12 (1997) 3913-3918
3. Beral V., Banks E., and Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360 9337 (2002) 942-944
4. C.G.o.H.F.i.B., Cancer, breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, Lancet 350 (9084) (1997) 1047-1059.
5. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., and Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332 24 (1995) 1589-1593
6. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., and Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer. 81 3 (1999) 339-344
7. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 4 (2000) 485-491
8. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
9. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., Gilligan M.A., Cyr M.G., Thomson C.A., Khandekar J., Petrovitch H., and McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 24 (2003) 3243-3253
10. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
11. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler. Thromb. Vasc. Biol. 22 2 (2002) 201-210
12. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92 4 (2000) 328-332
13. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., and Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 5A (2004) 2783-2840
14. Viereck V., Emons G., and Wuttke W. Black cohosh: just another phytoestrogen?. Trends Endocrinol. Metab. 16 5 (2005) 214-221
15. Cos P., De Bruyne T., Apers S., Vanden Berghe D., Pieters L., and Vlietinck A.J. Phytoestrogens: recent developments. Planta Med. 69 7 (2003) 589-599
16. Vollmer G., and Zierau O. What are phytoestrogens and phyto-SERMS. Pharm. Unserer. Zeit. 33 5 (2004) 378-383
17. Heger M., Ventskovskiy B.M., Borzenko I., Kneis K.C., Rettenberger R., Kaszkin-Bettag M., and Heger P.W. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause 13 5 (2006) 744-759
18. Park E.K., Choo M.K., Yoon H.K., Kim D.H., and Antithrombotic and antiallergic activities of rhaponticin from Rhei Rhizoma are activated by human intestinal bacteria. Arch. Pharm. Res. 25 4 (2002) 528-533
19. Kobashi K., and Akao T. Relation of intestinal bacteria to pharmacological effects of glycosides. Biosci. Microflora 16 (1997) 1-7
20. Kim D.H., Park E.K., Bae E.A., and Han M.J. Metabolism of rhaponticin and chrysophanol 8-o-beta-d-glucopyranoside from the rhizome of rheum undulatum by human intestinal bacteria and their anti-allergic actions. Biol. Pharm. Bull. 23 7 (2000) 830-833
21. Isaacson K.B., Galman M., Coutifaris C., and Lyttle C.R. Endometrial synthesis and secretion of complement component-3 by patients with and without endometriosis. Fertil. Steril. 53 5 (1990) 836-841
22. Sundstrom S.A., Komm B.S., Ponce-de-Leon H., Yi Z., Teuscher C., and Lyttle C.R. Estrogen regulation of tissue-specific expression of complement C3. J. Biol. Chem. 264 28 (1989) 16941-16947
23. Migliaccio A., Castoria G., de Falco A., Di Domenico M., Galdiero M., Nola E., Chambon P., and Auricchio F. In vitro phosphorylation and hormone binding activation of the synthetic wild type human estradiol receptor. J. Steroid Biochem. Mol. Biol. 38 4 (1991) 407-413
24. Routledge E., and Sumpter J.P. Oestrogenic activity of surfactants and some of their degradation products assessed using a recombinant yeast screen. Environ. Tox. Chem. 15 (1996) 241-248
25. Zierau O., Bodinet C., Kolba S., Wulf M., and Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. J. Steroid Biochem. Mol. Biol. 80 1 (2002) 125-130
26. Wober J., Weisswange I., and Vollmer G. Stimulation of alkaline phosphatase activity in Ishikawa cells induced by various phytoestrogens and synthetic estrogens. J. Steroid Biochem. Mol. Biol. 83 1-5 (2002) 227-233
27. Wakeling A.E., and Bowler J. Steroidal pure antioestrogens. J. Endocrinol. 112 3 (1987) R7-R10
28. Wakeling A.E., and Bowler J. ICI 182,780, a new antioestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 43 1-3 (1992) 173-177
29. Vollmer G., Ellerbrake N., Hopert A.C., Knauthe R., Wunsche W., and Knuppen R. Extracellular matrix induces hormone responsiveness and differentiation in RUCA-I rat endometrial adenocarcinoma cells. J. Steroid Biochem. Mol. Biol. 52 3 (1995) 259-269
30. Gehm B.D., Levenson A.S., Liu H., Lee E.J., Amundsen B.M., Cushman M., Jordan V.C., and Jameson J.L. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J. Steroid Biochem. Mol. Biol. 88 3 (2004) 223-234
31. Maggiolini M., Recchia A.G., Bonofiglio D., Catalano S., Vivacqua A., Carpino A., Rago V., Rossi R., and Ando S. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. J. Mol. Endocrinol. 35 2 (2005) 269-281
32. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., and Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 10 (1998) 4252-4263
33. Mueller S.O., Simon S., Chae K., Metzler M., and Korach K.S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci. 80 1 (2004) 14-25
34. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., and Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 3 (1997) 863-870
35. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., and Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141 10 (2000) 3657-3667
36. Zhu B.T., Han G.Z., Shim J.Y., Wen Y., and Jiang X.R. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 147 9 (2006) 4132-4150
37. Seidlova-Wuttke D., Becker T., Christoffel V., Jarry H., and Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J. Steroid Biochem. Mol. Biol. 86 2 (2003) 179-188
38. Cvoro A., Paruthiyil S., Jones J.O., Tzagarakis-Foster C., Clegg N.J., Tatomer D., Medina R.T., Tagliaferri M., Schaufele F., Scanlan T.S., Diamond M.I., Cohen I., and Leitman D.C. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 148 2 (2007) 538-547
39. Gusman J., Malonne H., and Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22 8 (2001) 1111-1117
40. Ryu S.Y., Han Y.N., and Han B.H. Monoamine oxidase-A inhibitors from medicinal plants. Arch. Pharm. Res. 11 (1988) 230-239
41. Andlauer W., Kolb J., and Furst P. Absorption and metabolism of genistin in the isolated rat small intestine. FEBS Lett. 475 2 (2000) 127-130
42. Browning A.M., Walle U.K., and Walle T. Flavonoid glycosides inhibit oral cancer cell proliferation-role of cellular uptake and hydrolysis to the aglycones. J. Pharm. Pharmacol. 57 8 (2005) 1037-1042
43. Konig J., Seithel A., Gradhand U., and Fromm M.F. Pharmacogenomics of human OATP transporters. Naunyn. Schmiedebergs Arch. Pharmacol. 372 6 (2006) 432-443
44. Boulware M.I., and Mermelstein P.G. The influence of estradiol on nervous system function. Drug News Perspect. 18 10 (2005) 631-637
45. Song R.X., Zhang Z., and Santen R.J. Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol. Metab. 16 8 (2005) 347-353
46. Filardo E.J., and Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab. 16 8 (2005) 362-367
47. Wade C.B., Robinson S., Shapiro R.A., and Dorsa D.M. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 142 6 (2001) 2336-2342
48. Rai D., Frolova A., Frasor J., Carpenter A.E., and Katzenellenbogen B.S. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Mol. Endocrinol. 19 6 (2005) 1606-1617
49. Lund T.D., Rovis T., Chung W.C., and Handa R.J. Novel actions of estrogen receptor-beta on anxiety-related behaviors. Endocrinology 146 2 (2005) 797-807
50. Imwalle D.B., Gustafsson J.A., and Rissman E.F. Lack of functional estrogen receptor beta influences anxiety behavior and serotonin content in female mice. Physiol. Behav. 84 1 (2005) 157-163
51. Krezel W., Dupont S., Krust A., Chambon P., and Chapman P.F. Increased anxiety and synaptic plasticity in estrogen receptor beta -deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98 21 (2001) 12278-12282
52. Walf A.A., Rhodes M.E., and Frye C.A. Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. Pharmacol. Biochem. Behav. 78 3 (2004) 523-529
53. Harris H.A., Katzenellenbogen J.A., and Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 143 11 (2002) 4172-4177
54. Gustafsson J.A. ERbeta scientific visions translate to clinical uses. Climacteric 9 3 (2006) 156-160